Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)

The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences psychiatrists’ treatment decisions, newer oral agents—such as Caplyta (Intra-Cellular Therapies, now acquired by Johnson & Johnson Innovative Medicine)—are striving to gain traction. The long-acting injectable (LAI) segment is evolving as well, driven by increasing competition and the introduction of new LAIs, including Lundbeck / Otsuka’s Abilify Asimtufii and Teva’s Uzedy, along with the generic availability of key LAIs. Bristol Myers Squibb’s novel drug, Cobenfy, was launched in late 2024 in the United States, and its anticipated approval in other countries will further strengthen its market presence. However, following the failure of Boehringer Ingelheim’s iclepertin in Phase 3 trials, a significant unmet need remains for effective treatments targeting the cognitive impairment associated with schizophrenia. As the market continues to evolve with newer brands competing with existing drugs, a comprehensive understanding of the schizophrenia landscape is essential for identifying future opportunities.

Questions answered

• What is the size of the schizophrenia therapy market in the G7 countries? Which key events will influence the market over the next decade?
• Which factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
• What are the areas of highest unmet need in schizophrenia treatment?
• What improvements would key late-phase therapies need to demonstrate to compete effectively in this market? How will these agents be placed in the schizophrenia treatment algorithm?

Content highlights

Release date: November 2025. Updated throughout the year to reflect Clarivate’s expert analysis of the latest major-market events

Geographies: United States, EU5, Japan

Primary research: 32 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research

Epidemiology: Prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; diagnosed / drug-treated prevalence of schizophrenia by country

Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.